Tonix Pharmaceuticals presented real-world data characterizing U.S. adults with fibromyalgia at ISPOR 2026, highlighting the substantial burden of the chronic pain disorder and treatment challenges faced by patients. The analysis of three years of closed claims data from Symphony Health focused on the study’s third year (2023-2024), comprising more than 261,000 U.S. adults with fibromyalgia.
Disease Burden and Comorbidities
Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, cognitive dysfunction, and somatic symptoms. The Year 3 cohort included 261,776 adult patients with a median age of 53 years, with 92.1% female. Comorbidity burden was high, with 93.2% of patients having at least one fibromyalgia-related comorbidity, most commonly anxiety/depression (63.9%), dorsalgia/back pain (56.5%), hypertensive diseases (51.4%), and joint pain (48.4%). Among the 90.3% of patients with at least one co-existing condition, 36.2% had four or more comorbidities.
Healthcare Resource Utilization and Treatment Patterns
Among insured patients (n=92,157), inpatient services represented the largest component of healthcare costs at $29,896 per patient annually, followed by pharmacy ($9,453) and outpatient ($6,196) costs. Antidepressants were the most frequently used medication class (48.2%), followed by NSAID analgesics (43.4%), anticonvulsants (41.6%), gastric acid secretion reducers (41.5%), skeletal muscle relaxants (40.7%), and opioid analgesics (39.4%). Tonix commercially launched TONMYA in November 2025, the first new fibromyalgia drug for adults in the U.S. approved in over 15 years.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/05/26/3300935/28908/en/Tonix-Pharmaceuticals-Presented-Retrospective-U-S-Real-World-Claims-Analysis-Characterizing-Patients-with-Fibromyalgia-at-The-Professional-Society-for-Health-Economics-and-Outcomes.html